Athera and Medirista Sign Agreement
News Aug 27, 2013
Athera Biotechnologies AB has announced that the rights to the recombinant Annexin A5 have been transferred to Medirista AB.
Medirista is a biotech company owned by the original innovators of the Annexin A5 project, Johan and Anna Frostegård.
The whole patent portfolio together with key preclinical assets have been transferred. Athera will continue its focus on development of the lead product candidate, the fully human antibody in atherosclerosis.
Recombinant Annexin A5 has been developed to preclinical stage by Athera as an anti-inflammatory therapy, primarily targeting prevention of complications following vascular surgery.
Annexin A5 has been shown to beneficially affect remodelling in a preclinical model of coronary bypass grafting. Another study showed that low doses of Annexin A5 could prevent injury in a model mimicking catheter-based percutaneous interventions (PCI) in mice.
Millions of PCI procedures are done per year due to acute coronary syndrome (ACS) and the number is rapidly increasing.
Could This Be a "Silver Bullet" for Preventing and Treating Colon Cancer?News
A team of scientists targeted the gene CtBP with a drug known as HIPP (2-hydroxy-imino phenylpyruvic acid) and were able to reduce the development of pre-cancerous polyps by half.READ MORE
Shedding Light on How Tumors Become Resistant to ImmunotherapyNews
Researchers have now found that in skin cutaneous melanoma an epigenetic control protein is key to the development of immunotherapy resistance.READ MORE